Summary

Influenza Diagnostics Market – Scope of Report
TMR’s report on the global influenza diagnostics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global influenza diagnostics market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global influenza diagnostics market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the influenza diagnostics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global influenza diagnostics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global influenza diagnostics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global influenza diagnostics market.

The report delves into the competitive landscape of the global influenza diagnostics market. Key players operating in the global influenza diagnostics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global influenza diagnostics market profiled in this report.

Key Questions Answered in Global influenza diagnostics Market Report
• What is the sales/revenue generated by influenza diagnostics across all regions during the forecast period?
• What are the opportunities in the global influenza diagnostics market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Influenza Diagnostics Market – Research Objectives and Research Approach
The comprehensive report on the global influenza diagnostics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global influenza diagnostics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global influenza diagnostics market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Influenza Diagnostics Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Influenza Diagnostics Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Disease Epidemiology
5.2. Reimbursement Scenario
5.3. COVID-19 Pandemic Impact on Industry
6. Global Influenza Diagnostics Market Analysis and Forecast, by Flu Virus Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Flu Virus Type, 2017–2031
6.3.1. Type A
6.3.2. Type B
6.4. Market Attractiveness Analysis, by Flu Virus Type
7. Global Influenza Diagnostics Market Analysis and Forecast, by Test Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Test Type, 2017–2031
7.3.1. RT-PCR Tests
7.3.2. Rapid Influenza Diagnostic Tests (RIDTs)
7.3.3. Viral Culture
7.3.4. Immunofluorescence Assays
7.3.5. Serological Tests
7.3.6. Others (LAMP, SAMBA, etc.)
7.4. Market Attractiveness Analysis, by Test Type
8. Global Influenza Diagnostics Market Analysis and Forecast, by Product Type
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Product Type, 2017–2031
8.3.1. Kits & Reagents
8.3.2. Instrument
8.3.3. Others
8.4. Market Attractiveness Analysis, by Product Type
9. Global Influenza Diagnostics Market Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by End-user, 2017–2031
9.3.1. Hospitals
9.3.2. Diagnostic Centers
9.3.3. Others (academics & research institutes, etc.)
9.4. Market Attractiveness Analysis, by End-user
10. Global Influenza Diagnostics Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Region
11. North America Influenza Diagnostics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Flu Virus Type, 2017–2031
11.2.1. Type A
11.2.2. Type B
11.3. Market Value Forecast, by Test Type, 2017–2031
11.3.1. RT-PCR Tests
11.3.2. Rapid Influenza Diagnostic Tests (RIDTs)
11.3.3. Viral Culture
11.3.4. Immunofluorescence Assays
11.3.5. Serological Tests
11.3.6. Others (LAMP, SAMBA, etc.)
11.4. Market Value Forecast, by Product Type, 2017–2031
11.4.1. Kits & Reagents
11.4.2. Instrument
11.4.3. Others
11.5. Market Value Forecast, by End-user, 2017–2031
11.5.1. Hospitals
11.5.2. Diagnostic Centers
11.5.3. Others (academics & research institutes, etc.)
11.6. Market Value Forecast, by Country, 2017–2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Flu Virus Type
11.7.2. By Test Type
11.7.3. By Product Type
11.7.4. By End-user
11.7.5. By Country
12. Europe Influenza Diagnostics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Flu Virus Type, 2017–2031
12.2.1. Type A
12.2.2. Type B
12.3. Market Value Forecast, by Test Type, 2017–2031
12.3.1. RT-PCR Tests
12.3.2. Rapid Influenza Diagnostic Tests (RIDTs)
12.3.3. Viral Culture
12.3.4. Immunofluorescence Assays
12.3.5. Serological Tests
12.3.6. Others (LAMP, SAMBA, etc.)
12.4. Market Value Forecast, by Product Type, 2017–2031
12.4.1. Kits & Reagents
12.4.2. Instrument
12.4.3. Others
12.5. Market Value Forecast, by End-user, 2017–2031
12.5.1. Hospitals
12.5.2. Diagnostic Centers
12.5.3. Others (academics & research institutes, etc.)
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Flu Virus Type
12.7.2. By Test Type
12.7.3. By Product Type
12.7.4. By End-user
12.7.5. By Country/Sub-region
13. Asia Pacific Influenza Diagnostics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Flu Virus Type, 2017–2031
13.2.1. Type A
13.2.2. Type B
13.3. Market Value Forecast, by Test Type, 2017–2031
13.3.1. RT-PCR Tests
13.3.2. Rapid Influenza Diagnostic Tests (RIDTs)
13.3.3. Viral Culture
13.3.4. Immunofluorescence Assays
13.3.5. Serological Tests
13.3.6. Others (LAMP, SAMBA, etc.)
13.4. Market Value Forecast, by Product Type, 2017–2031
13.4.1. Kits & Reagents
13.4.2. Instrument
13.4.3. Others
13.5. Market Value Forecast, by End-user, 2017–2031
13.5.1. Hospitals
13.5.2. Diagnostic Centers
13.5.3. Others (academics & research institutes, etc.)
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Flu Virus Type
13.7.2. By Test Type
13.7.3. By Product Type
13.7.4. By End-user
13.7.5. By Country/Sub-region
14. Latin America Influenza Diagnostics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Flu Virus Type, 2017–2031
14.2.1. Type A
14.2.2. Type B
14.3. Market Value Forecast, by Test Type, 2017–2031
14.3.1. RT-PCR Tests
14.3.2. Rapid Influenza Diagnostic Tests (RIDTs)
14.3.3. Viral Culture
14.3.4. Immunofluorescence Assays
14.3.5. Serological Tests
14.3.6. Others (LAMP, SAMBA, etc.)
14.4. Market Value Forecast, by Product Type, 2017–2031
14.4.1. Kits & Reagents
14.4.2. Instrument
14.4.3. Others
14.5. Market Value Forecast, by End-user, 2017–2031
14.5.1. Hospitals
14.5.2. Diagnostic Centers
14.5.3. Others (academics & research institutes, etc.)
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Flu Virus Type
14.7.2. By Test Type
14.7.3. By Product Type
14.7.4. By End-user
14.7.5. By Country/Sub-region
15. Middle East & Africa Influenza Diagnostics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Flu Virus Type, 2017–2031
15.2.1. Type A
15.2.2. Type B
15.3. Market Value Forecast, by Test Type, 2017–2031
15.3.1. RT-PCR Tests
15.3.2. Rapid Influenza Diagnostic Tests (RIDTs)
15.3.3. Viral Culture
15.3.4. Immunofluorescence Assays
15.3.5. Serological Tests
15.3.6. Others (LAMP, SAMBA, etc.)
15.4. Market Value Forecast, by Product Type, 2017–2031
15.4.1. Kits & Reagents
15.4.2. Instrument
15.4.3. Others
15.5. Market Value Forecast, by End-user, 2017–2031
15.5.1. Hospitals
15.5.2. Diagnostic Centers
15.5.3. Others (academics & research institutes, etc.)
15.6. Market Value Forecast, by Country/Sub-region, 2017–2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Flu Virus Type
15.7.2. By Test Type
15.7.3. By Product Type
15.7.4. By End-user
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (by tier and size of companies)
16.2. Market Share Analysis, by Company (2022)
16.3. Company Profiles
16.3.1. 3M
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Abbott
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. F. Hoffmann-La Roche Ltd.
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Becton, Dickinson and Company
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. BIOMÉRIEUX
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Bio-Rad Laboratories, Inc.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Goldsite Diagnostics Inc.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Hologic, Inc.
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. DiaSorin S.p.A.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Meridian Bioscience, Inc.
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
16.3.11. QuidelOrtho Corporation
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Product Portfolio
16.3.11.3. Financial Overview
16.3.11.4. SWOT Analysis
16.3.11.5. Strategic Overview
16.3.12. SA Scientific Ltd.
16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.12.2. Product Portfolio
16.3.12.3. Financial Overview
16.3.12.4. SWOT Analysis
16.3.12.5. Strategic Overview
16.3.13. Sekisui Diagnostics
16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.13.2. Product Portfolio
16.3.13.3. Financial Overview
16.3.13.4. SWOT Analysis
16.3.13.5. Strategic Overview
16.3.14. Siemens Healthineers
16.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.14.2. Product Portfolio
16.3.14.3. Financial Overview
16.3.14.4. SWOT Analysis
16.3.14.5. Strategic Overview
16.3.15. Thermo Fisher Scientific
16.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.15.2. Product Portfolio
16.3.15.3. Financial Overview
16.3.15.4. SWOT Analysis
16.3.15.5. Strategic Overview